ReviewCureus2026
FLASH Radiotherapy in Lung Cancer: Translational Mechanisms, Preclinical Evidence, and Barriers.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This narrative review aims to compile the preclinical and translational information about FLASH radiotherapy (FLASH-RT) as a lung cancer therapy. Experimental studies on animal and ex vivo human models have shown that FLASH-RT reduces lung fibrosis and inflammation while maintaining tumor control. The "FLASH effect" is most likely brought on by immunological remodeling, reactive oxygen species (ROS) control, and brief oxygen deprivation. Proton pencil beam scanning (PBS), Bragg peak modulation, and adaptive planning are some of the innovative techniques that have contributed to improvements in high-dose-rate delivery accuracy. When it comes to real-time dosimetry, mobility management, and the standardization of dose-rate data, however, there are still hurdles to encounter. It is necessary to do more research that will include several disciplines, including biology, physics, and clinical innovation, to facilitate safe clinical translation. This review seeks to elucidate existing issues, identify information deficiencies, and inform future research and clinical trial design for FLASH-RT-based lung cancer treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.